Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study

This two-part, open-label, phase 1/2a study suggests that the combination of ibrutinib plus nivolumab has a manageable safety profile for patients with relapsed/refractory high-risk chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), follicular lymphoma (FL), or diffuse large B-cell lymphoma, with the most common grade 3/4 adverse events (AEs) being neutropenia (28%) and anemia (23%) in the total patient population (N = 141). Rates of treatment discontinuation due to adverse events were higher with the combination regimen (31% in the CLL and SLL cohorts, and 28% in the FL cohort), compared with 4% among similar CLL patient populations receiving single-agent ibrutinib in other studies. 

Lancet Haematology